Access Challenges in Retinal Vascular Diseases

This episode, titled “Access Challenges in Retinal Vascular Diseases,” features panelists discussing the real-world barriers that affect implementation of anti-VEGF therapies and long-term disease management across retinal vascular diseases. The expert faculty explore how patient adherence, insurance restrictions, treatment burden, and financial limitations continue to shape treatment decisions in AMD, DME, DR, and retinal vein occlusion.

Throughout the discussion, the panel highlights the clinical impact of missed visits and loss to follow-up, particularly among younger patients with diabetes who often face competing medical, family, and work responsibilities. The expert faculty describe how durability and extended treatment intervals may help reduce the burden of frequent office visits while providing greater reassurance when patients are unable to return on schedule.

The panelists also discuss the complexity of navigating insurance coverage for next-generation anti-VEGF therapies, including prior authorizations, step therapy requirements, biosimilar mandates, and limitations imposed by assistance program funding. The expert faculty explain how these barriers can complicate treatment selection and restrict access to therapies that may offer improved durability and disease control. At the same time, the panel acknowledges the continued importance of bevacizumab as an affordable and accessible treatment option for many patients, particularly when financial barriers limit use of newer agents.

In addition, the discussion highlights the growing role of manufacturer-sponsored assistance programs in helping uninsured and underinsured patients gain access to advanced therapies. Overall, the panel emphasizes that successful management of retinal vascular diseases requires balancing efficacy, durability, patient adherence, and real-world access considerations.

The next episode in this series, “Future Treatment Strategies in Retinal Vascular Diseases,” features the panelists discussing emerging therapies including TKIs, gene therapy, and next-generation biologics for AMD, DME, DR, and retinal vein occlusion. The expert faculty also share final perspectives on innovation, durability, safety, and the future evolution of retinal vascular disease management.